Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NBTY on ephedra ban

This article was originally published in The Tan Sheet

Executive Summary

"We actually look forward to FDA being more active in [regulating] products," CFO Harvey Kamil stated Jan. 22 in response to a question on what NBTY's feelings were regarding the agency's upcoming ban on ephedrine alkaloid-containing dietary supplements. "We do not want products that are unsafe on the marketplace. They have the authority to take products off the marketplace. We want them to use that authority," he added. FDA's final rule banning the controversial ingredient was forwarded to OMB Jan. 22, where it is awaiting final approval (see story, p. 12)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel